Want to join the conversation?
Integrated orthopedic medicines company $ANIK said it received CE Mark approval for CINGAL as a medical device to treat pain associated with osteoarthritis of the knee. CINGAL is the first and only commercially-available combination viscosupplement, formulated with $ANIK's proprietary cross-linked sodium hyaluronate and triamcinolone hexacetonide.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.